Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2017

View Archived Issues

FDA clears Recardio's IND for development of dutogliptin for acute myocardial infarction

Compugen selects COM-902 as immuno-oncology antibody candidate

Oncology Venture in-licenses 2-BBB's 2B3-101 for 2X Oncology's pipeline

Targapremir-210 is a small molecule inhibitor of miR-210 that reprograms oncogenic hypoxic circuit

S3F-CL-MMAE as a novel anti-STn ADC with promising antitumor activity in vivo

FDA allows IND for clinical trials of Oratopo

New ghrelin receptor agonist AZ-4558 shows reduced mechanism-related side effects

European orphan drug designation for Epidiolex for Lennox-Gastaut syndrome

Novel SARDs UT-69 and UT-155 show proof-of concept and efficacy in a prostate cancer xenograft model

EMA grants orphan drug designation to inebilizumab for neuromyelitis optica spectrum disorder

Jazz licenses Japanese rights for Defitelio and Vyxeos to Nippon Shinyaku

VL#FIA3-30 demonstrates efficacy in the treatment of erectile dysfunction

Vertex plans regulatory filings following phase III results for tezacaftor/ivacaftor

Avillion and Merck KGaA sign codevelopment agreement for IL-17 A/F Nanobody in plaque psoriasis

FDA grants priority review to BLA filing for CTL-019 for relapsed or refractory B-cell ALL

Interim data from phase Ib study of DPX-Survivac with epacadostat in ovarian cancer

Altimmune receives contract modification from BARDA to fund manufacturing of NasoShield

First patient dosed in phase I trial of JHL-1101 in rheumatoid arthritis

Hanmi Pharmaceutical and Innovent Biologics establish immuno-oncology partnership

VenatoRx Pharmaceuticals presents novel beta-lactamase inhibitors

Selvita announces global license agreement with Menarini for SEL-24

Glenmark reports phase III results for GSP-301 in seasonal allergic rhinitis

GlaxoSmithKline Intellectual Property identifies PERK inhibitors

Qiagen launches ipsogen JAK2 assay for polycythemia vera

FDA grants priority review to Blincyto sBLA

Shanghai Jingxin Biomedical and partners patent dopamine D2 and 5-HT1A receptor ligands

Warp Drive Bio collaborates with GSK to discover new therapeutics

ViiV Healthcare divulges benzoazepine derivatives

Redx Pharma discovers antibacterial compounds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...